Eli Lilly considers BMS trademark opposition

Eli Lilly appears to be mulling whether to oppose a trademark registered by Bristol-Myers Squibb (BMS) at the US Patent and Trademark Office.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Eli Lilly refused injunction against Teva, Actavis and Mylan

17 November 2017 The English High Court has refused to grant Eli Lilly an injunction which would have stopped Teva, Actavis and Mylan marketing a generic version of its drug Cialis (tadalafil).

Big Pharma

Eli Lilly defeated as Cialis patent found obvious on appeal

1 November 2017 The English Court of Appeal has ruled that patent claims protecting blockbuster drug Cialis (tadalafil) are invalid as obvious, handing victory to Actavis, Teva and Mylan.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Eli Lilly considers BMS trademark opposition

More on this story

Editor's picks

Editor's picks

More features